BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2146723)

  • 1. Antiandrogenic substances in the management of prostatic cancer.
    Schröder FH
    Recent Results Cancer Res; 1990; 118():163-73. PubMed ID: 2146723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
    Sogani PC; Whitmore WF
    Cancer Treat Res; 1988; 39():131-45. PubMed ID: 2908604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH
    Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer of the prostate. Mechanisms of action of antiandrogens.
    Habenicht UF; Neumann F; el Etreby MF
    Acta Urol Belg; 1991; 59(4):1-10. PubMed ID: 1840231
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
    de Voogt HJ
    Prostate Suppl; 1992; 4():91-5. PubMed ID: 1533452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiandrogens: clinical applications.
    Sciarra F; Toscano V; Concolino G; Di Silverio F
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):349-62. PubMed ID: 2147859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of antiandrogens.
    Namer M
    J Steroid Biochem; 1988 Oct; 31(4B):719-29. PubMed ID: 2462132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    Di Silverio F; Sciarra F; D'Eramo G
    Eur Urol; 1990; 18(1):10-5. PubMed ID: 2144819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
    Soloway MS; Matzkin H
    Cancer; 1993 Feb; 71(3 Suppl):1083-8. PubMed ID: 8428332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
    Schröder FH; Collette L; de Reijke TM; Whelan P
    Br J Cancer; 2000 Jan; 82(2):283-90. PubMed ID: 10646878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
    Labrie C; Cusan L; Plante M; Lapointe S; Labrie F
    J Steroid Biochem; 1987 Oct; 28(4):379-84. PubMed ID: 2444770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of antiandrogens.
    Neumann F; Töpert M
    J Steroid Biochem; 1986 Nov; 25(5B):885-95. PubMed ID: 2949114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.